| Drug-delivery endovascular stent and method of use -> Monitor Keywords |
|
|
  Drug-delivery endovascular stent and method of useUSPTO Application #: 20080097591Title: Drug-delivery endovascular stent and method of use Abstract: An improvement in drug-eluting stents, and method of their making are disclosed. The surface of a metal stent is roughened to have a surface roughness of at least about 20 μin (0.5 μm) and a surface roughness range of between about 300-700 μin (7.5-17.5 μm). The roughened stent surface is covered with a polymer-free coating of a limus drug, to a coating thickness greater than the range of surface roughness of the roughened stent surface. (end of abstract) Agent: Perkins Coie LLP - Menlo Park, CA, US Inventors: Douglas R. Savage, John E. Shulze, Ronald E. Betts, Sepehr Fariabi, Shih-Horng Su USPTO Applicaton #: 20080097591 - Class: 623 143 (USPTO) The Patent Description & Claims data below is from USPTO Patent Application 20080097591. Brief Patent Description - Full Patent Description - Patent Application Claims
CROSS-REFERENCE TO RELATED APPLICATIONS [0001]This application claims the benefit of priority to U.S. Provisional Application No. 60/853,077, filed Oct. 20, 2006, and U.S. patent application Ser. No. 11/690,768, filed Mar. 27, 2007, both of which are incorporated herein by reference in their entirety. TECHNICAL FIELD [0002]The present application relates to an endovascular stent at least partly including a textured or abraded surface, and a method of making and using the stent. BACKGROUND [0003]Complications such as restenosis are a recurring problem in patients who have received artherosclerosis therapy in the form of medical procedures such as percutaneous translumenal coronary angioplasty (PTCA). Restenosis is commonly treated by a procedure known as stenting, where a medical device is surgically implanted in the affected artery to prevent it from occluding post procedure. [0004]A stent is typically cylindrical in shape and is usually made from a biocompatible metal, such as cobalt chromium or surgical steel. Most stents are collapsible and are delivered to the occluded artery via a translumenal catheter. The stent is affixed to the catheter and can be either self expanding or expanded by inflation of a balloon inside the stent that is then removed with the catheter once the stent is in place. [0005]Complications that can arise from stent therapy include restenosis and thrombosis. In an effort to overcome these complications, stents may contain a layer or coating of an anti-restenosis drug that is released in a controlled fashion at the stent-implantation site. Typically, the drug is contained in a permanent or bioerodable polymer carrier, as disclosed, for example, in U.S. Pat. No. 5,716,981 issued to Hunter entitled "Anti-angiogenic Compositions and Methods of Use." Examples of typical therapies that are proposed to be delivered in this manner are antiproliferatives, anticoagulants, anti-inflammatory agents and immunosuppressive agents, although there are many other chemical and biological agents also mentioned in the patent literature. It has been suggested that the polymer carrier with drug may be covered by a porous biodegradable layer that serves to regulate controlled release of the drug into the body, as disclosed for example, in U.S. Pat. Nos. 6,774,278 and 6,730,064. [0006]More recently, stents in which an anti-restenosis drug is carried in channels, grooves or pores for release in "polymer-free" i.e. pure-drug form have been proposed. Alternatively, stents having roughened surface intended to anchor a drug layer on the surface of the stent, for release in pure-drug form have been proposed, for example, in U.S. Pat. Nos. 6,805,898 and 6,918,927. None of these patents show or suggest that with particular classes of anti-restenosis compounds, it is possible to enhance the anti-restenosis activity of the compounds by selection of surface roughness features within certain ranges on the stent surface. [0007]In light of the complications associated with stent therapy, it would be desirable to develop a stent having at least one roughened or textured surface for increased surface area, which can be manufactured in such a way as to maximize structural integrity, drug loading capacity, and ability to deliver drug to the vessel wall in a therapeutically enhanced way, as evidenced by a reduced risk of rate of occurrence or extent of restenosis following stent placement at the site of vascular injury. SUMMARY [0008]The invention includes, in one embodiment, an improvement in a method for reducing the rate of occurrence and/or extent of restenosis or thrombosis resulting from vascular injury in a subject, relative to that observed by placing at the site of injury, a smooth-surfaced expandable stent formed of interconnected metal filaments, by coating the outer surface of the stent filaments with a polymer carrier containing a limus drug. The improvement, which is intended to maintain or further reduce the rate of occurrence and/or extent of restenosis or thrombosis, relative to that achieved with a polymer-coated, limus-eluting stent, but without the presence of a polymer carrier, includes the steps of: [0009](a) roughening outer surface regions of the stent filaments to a surface roughness of at least about 20 .mu.in (0.5 .mu.m), and a surface roughness range (maximum peak-to-valley) of between about 300-700 .mu.in (7.5-17.5 .mu.m), and [0010](b) coating the roughened regions of the stent filaments with a polymer-free coating of the limus drug, to a coating thickness greater than the surface roughness range of the roughened stent surface, that is, to a thickness that covers the roughened surface. [0011]The stent filaments may be roughened to have a surface roughness of between about 20-40 .mu.in (0.5 to 1 .mu.m), and/or a surface roughness range of between about 300-500 .mu.in (7.5-12.5 .mu.m). [0012]The surface roughening may be carried out by abrading the outer surface regions of the stent filaments with a pressurized stream of abrasive particles, by forming a hydrocarbon-film mask over outer surface regions of the stent filaments, selectively removing stent material exposed by the mask, and removing the mask, by laser etching the outer surface regions of the stent filaments, or by peening the outer surface regions of the filaments to imprint a pattern thereon. [0013]The drug coating may be applied as a viscous solution of the drug onto the outer surfaces of the stent filament, with drying to form a solid drug coating on the stent filaments. The coating may be applied to a final amount of limus drug on the stent between 25 to 240 ug/cm stent length, and to a final coating thickness between 5 and 15 .mu.m. One preferred class of limus drugs are the 42-0-alkoxyalkyl limus compounds, as exemplified by the 42-O-ethoxyethyl compound referred to herein as Biolimus A9. [0014]In another aspect, the invention includes an improvement in a method for administering an anti-restenosis drug from an expandable stent formed of interconnected metal filaments, by coating the outer surface of the stent with a polymer-free limus drug coating. The improvement, which is intended to reduce the rate of occurrence and/or extent of restenosis or thrombosis achieved with the polymer-free limus drug coating, comprises roughening the outer surface regions of the stent filaments which are coated by the limus drug, to a surface roughness of at least about 20 .mu.in (0.5 .mu.m), and a surface roughness range of between about 300-700 .mu.in (7.5-17.5 .mu.m). [0015]Also disclosed is an expandable stent for use in reducing the rate of occurrence and/or extent of restenosis or thrombosis resulting when the stent is placed at a site of vascular injury. The stent includes an expandable stent body formed of interconnected metal filaments, and formed on outer surface regions of the stent filaments, a roughened surface characterized by a surface roughness of at least about 20 .mu.in (0.5 .mu.m), and a surface roughness range of between about 300-700 .mu.in (7.5-17.5 .mu.m), and carried on the roughened regions of the stent filaments, a polymer-free coating of the limus drug having a coating thickness greater than the range of surface roughness of the roughened stent surface. [0016]These and other aspects and embodiments of the present invention will become better apparent in view of the detailed description in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS [0017]FIG. 1 is a scanned image of an endovascular stent having a metal filament body; [0018]FIG. 2A is a scanning electron micrograph of an abraded stent surface; [0019]FIG. 2B is a scanning electron micrograph of the surface of FIG. 2A showing quantification of peaks generated on the stent surface after abrasion; Continue reading... Full patent description for Drug-delivery endovascular stent and method of use Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Drug-delivery endovascular stent and method of use patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Drug-delivery endovascular stent and method of use or other areas of interest. ### Previous Patent Application: Systems and methods for producing a medical device Next Patent Application: Intraventricular cardiac prosthesis Industry Class: Prosthesis (i.e., artificial body members), parts thereof, or aids and accessories therefor ### FreshPatents.com Support Thank you for viewing the Drug-delivery endovascular stent and method of use patent info. IP-related news and info Results in 4.8279 seconds Other interesting Feshpatents.com categories: Computers: Graphics , I/O , Processors , Dyn. Storage , Static Storage , Printers |
||
